135 related articles for article (PubMed ID: 11551512)
1. Inhibition of extracellular Ca(2+) entry by YC-1, an activator of soluble guanylyl cyclase, through a cyclic GMP-independent pathway in rat neutrophils.
Wang JP; Chang LC; Huang LJ; Kuo SC
Biochem Pharmacol; 2001 Sep; 62(6):679-84. PubMed ID: 11551512
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of superoxide anion generation by YC-1 in rat neutrophils through cyclic GMP-dependent and -independent mechanisms.
Wang JP; Chang LC; Raung SL; Hsu MF; Huang LJ; Kuo SC
Biochem Pharmacol; 2002 Feb; 63(4):577-85. PubMed ID: 11992625
[TBL] [Abstract][Full Text] [Related]
3. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway.
Hwang TL; Hung HW; Kao SH; Teng CM; Wu CC; Cheng SJ
Mol Pharmacol; 2003 Dec; 64(6):1419-27. PubMed ID: 14645672
[TBL] [Abstract][Full Text] [Related]
4. Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat.
Wegener JW; Gath I; Förstermann U; Nawrath H
Br J Pharmacol; 1997 Dec; 122(7):1523-9. PubMed ID: 9421305
[TBL] [Abstract][Full Text] [Related]
5. Interference of neutrophil-platelet interaction by YC-1: a cGMP-dependent manner on heterotypic cell-cell interaction.
Liao CH; Cheng JT; Teng CM
Eur J Pharmacol; 2005 Sep; 519(1-2):158-67. PubMed ID: 16112105
[TBL] [Abstract][Full Text] [Related]
6. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
[TBL] [Abstract][Full Text] [Related]
7. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.
Mülsch A; Bauersachs J; Schäfer A; Stasch JP; Kast R; Busse R
Br J Pharmacol; 1997 Feb; 120(4):681-9. PubMed ID: 9051308
[TBL] [Abstract][Full Text] [Related]
8. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase.
Wohlfart P; Malinski T; Ruetten H; Schindler U; Linz W; Schoenafinger K; Strobel H; Wiemer G
Br J Pharmacol; 1999 Nov; 128(6):1316-22. PubMed ID: 10578147
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of tumor necrosis factor-alpha expression by YC-1 in alveolar macrophages through a cyclic GMP-independent pathway.
Hwang TL; Wu CC; Guh JH; Teng CM
Biochem Pharmacol; 2003 Jul; 66(1):149-56. PubMed ID: 12818375
[TBL] [Abstract][Full Text] [Related]
10. The blockade of cyclopiazonic acid-induced store-operated Ca2+ entry pathway by YC-1 in neutrophils.
Wang JP; Chen YS; Tsai CR; Huang LJ; Kuo SC
Biochem Pharmacol; 2004 Nov; 68(10):2053-64. PubMed ID: 15476676
[TBL] [Abstract][Full Text] [Related]
11. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.
Galle J; Zabel U; Hübner U; Hatzelmann A; Wagner B; Wanner C; Schmidt HH
Br J Pharmacol; 1999 May; 127(1):195-203. PubMed ID: 10369473
[TBL] [Abstract][Full Text] [Related]
12. YC-1 attenuates homotypic human neutrophil aggregation through inhibition of phosphodiesterase activity.
Hwang TL; Zhuo SK; Pan YL
Eur J Pharmacol; 2008 Jan; 579(1-3):395-402. PubMed ID: 18001706
[TBL] [Abstract][Full Text] [Related]
13. YC-1-inhibited proliferation of rat mesangial cells through suppression of cyclin D1-independent of cGMP pathway and partially reversed by p38 MAPK inhibitor.
Chiang WC; Teng CM; Lin SL; Chen YM; Tsai TJ; Hsieh BS
Eur J Pharmacol; 2005 Jul; 517(1-2):1-10. PubMed ID: 15950964
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the role of nitric oxide and cyclic GMP in both the activation and inhibition of human neutrophils.
Wanikiat P; Woodward DF; Armstrong RA
Br J Pharmacol; 1997 Nov; 122(6):1135-45. PubMed ID: 9401778
[TBL] [Abstract][Full Text] [Related]
15. YC-1 potentiates the antiplatelet effect of hydrogen peroxide via sensitization of soluble guanylate cyclase.
Wu CC; Kuo SC; Lee FY; Teng CM
Eur J Pharmacol; 1999 Sep; 381(2-3):185-91. PubMed ID: 10554886
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole.
Chien WL; Liang KC; Teng CM; Kuo SC; Lee FY; Fu WM
Mol Pharmacol; 2003 Jun; 63(6):1322-8. PubMed ID: 12761342
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Apr; 317(1):258-66. PubMed ID: 16352702
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of superoxide anion generation by CHS-111 via blockade of the p21-activated kinase, protein kinase B/Akt and protein kinase C signaling pathways in rat neutrophils.
Chang LC; Lin RH; Huang LJ; Chang CS; Kuo SC; Wang JP
Eur J Pharmacol; 2009 Aug; 615(1-3):207-17. PubMed ID: 19445920
[TBL] [Abstract][Full Text] [Related]
19. Modulation of neutrophil migration by exogenous gaseous nitric oxide.
VanUffelen BE; de Koster BM; Van den Broek PJ; VanSteveninck J; Elferink JG
J Leukoc Biol; 1996 Jul; 60(1):94-100. PubMed ID: 8699130
[TBL] [Abstract][Full Text] [Related]
20. The soluble guanylyl cyclase activator YC-1 increases intracellular cGMP and cAMP via independent mechanisms in INS-1E cells.
Ramos-Espiritu LS; Hess KC; Buck J; Levin LR
J Pharmacol Exp Ther; 2011 Sep; 338(3):925-31. PubMed ID: 21665942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
